INVESTOR ALERT: Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated Announced by Glancy Binkow & Goldberg LLP
July 01 2014 - 10:32AM
Business Wire
Glancy Binkow & Goldberg LLP announces that a class action
lawsuit has been filed in the United States District Court for the
District of Massachusetts on behalf of a class (the “Class”)
comprising all purchasers of the common stock of Vertex
Pharmaceuticals Incorporated (“Vertex” or the “Company”)
(NASDAQ:VRTX) between May 7, 2012 and May 29, 2012, inclusive (the
“Class Period”).
Please contact us at (646) 539-8980, or at
shareholders@glancylaw.com to discuss this matter. If you inquire
by email please include your mailing address, telephone number and
number of shares purchased.
Vertex is engaged in discovering, developing, manufacturing and
commercializing small molecule drugs for patients with serious
diseases. The Company markets Kalydeco in the United States and
European Union as a treatment for patients aged six years and older
with a rare form of cystic fibrosis. The Complaint alleges that the
Company issued false and misleading public statements concerning
Vertex’s products VX-809 and Kalydeco.
On May 29, 2012, the Company issued a correction of the interim
analysis of the Phase 2 Combination Study of VX-809 and Kalydeco,
stating that the correction was due to a “misinterpretation”
between Vertex and a third-party statistical analysis vendor over
the study data. Following this news, the Company’s stock price
plummeted from its previous closing price of $64.85 on May 25,
2012, to close at $57.80 per share on May 29, 2012.
If you are a member of the Class described above, you may move
the Court no later than July 28, 2014, to serve as lead plaintiff,
if you meet certain legal requirements. To be a member of the Class
you need not take any action at this time; you may retain counsel
of your choice or take no action and remain an absent member of the
Class. If you wish to learn more about this action, or have any
questions concerning this announcement or your rights or interests
with respect to these matters, please contact Lesley Portnoy,
Esquire, of Glancy Binkow & Goldberg LLP, 122 E. 42nd Street,
Suite 2920, New York, New York 10168, at (646) 539-8980, by e-mail
to shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email, please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, New York, NYLesley Portnoy,
646-539-8980shareholders@glancylaw.comwww.glancylaw.com
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024